Moderna – at the moment embroiled in a patent dispute with Pfizer and BioNTech over mRNA intellectual property – is also testing a vaccine that combines COVID-19 and flu in a single jab in a ...

GSK has upgraded its longstanding alliance with CureVac on mRNA-based vaccines for respiratory infections, paying €400 million ($429 million) upfront for global rights to its influenza and COVID ...

Based on an immunogenicity screen of monkeypox virus (MPXV) surface proteins, the authors develop an mRNA vaccine with 12 antigens, which they combine with T cell epitope-rich regions to achieve ...

Build financial models with decades of earnings stats, ratios, and valuation data — all exportable — to power your trade ideas.